Medifast Inc (MED) stock
MEDNYSEMiscellaneous Food Preparations & Kindred ProductsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 26, 2026Score 10/3056% below fair value
$12.54−0.43 (-3.32%)
Close on Nov 16, 2026Market cap $140.23MP/E –Yield 0.00%
Medifast r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was $4.30M, down 6.5% from the year before. Over ten years it grew 9.1% a year on average. The highest annual figure on record is $4.60M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.30M | -6.5% |
| FY2024 | Dec 31, 2024 | $4.60M | 0.0% |
| FY2023 | Dec 31, 2023 | $4.60M | +2.2% |
| FY2022 | Dec 31, 2022 | $4.50M | +2.3% |
| FY2021 | Dec 31, 2021 | $4.40M | +57.1% |
| FY2020 | Dec 31, 2020 | $2.80M | +3.7% |
| FY2019 | Dec 31, 2019 | $2.70M | +22.7% |
| FY2018 | Dec 31, 2018 | $2.20M | +46.7% |
| FY2017 | Dec 31, 2017 | $1.50M | -25.0% |
| FY2016 | Dec 31, 2016 | $2.00M | +11.1% |
| FY2015 | Dec 31, 2015 | $1.80M | +38.5% |
| FY2014 | Dec 31, 2014 | $1.30M | – |
See a number that looks wrong?